215 First Street
About Eleven BiotherapeuticsEleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. Eleven’s therapeutic approach is based on the role of cytokines in diseases of the eye, the Company’s understanding of the structural biology of cytokines and the Company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects.
Founder: Reza Dana, K. Christopher Garcia, Greg Verdine, Casey Weaver, K. Dane Wittrup
CEO: Abbie Celniker
CMO (Medical): Michael Goldstein
Please click here for Eleven Biotherapeutics.
120 articles with Eleven Biotherapeutics
Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.
Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
May 21, 2018 18:15 UTC Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients Sesen Bio (Formally Eleven Biotherapeutics) Reports Positive, Three-Month Data from VISTA Trial of Vicinium™ in High-Grade NMIBC Data Presented During Plenary Session at American Urological Association Annual Meeting Company to Host Co
Name Change Reflects Company’s Focus on Late-Stage Oncology Drug Development
5/16/2018Eleven Biotherapeutics is rebranding itself as Sesen Bio and investors are pleased. This morning shares of Eleven are up more than 4 percent in premarket trading.
New Preclinical Data Highlighting Eleven Biotherapeutics’ DeBouganin Program to be Presented at 2018 AACR Annual Meeting
The meeting is taking place April 14-18, 2018 in Chicago.
Preliminary Data from Phase 3 VISTA Trial in Bladder Cancer to Be Presented in a Plenary Session at American Urological Association Annual Meeting
Eleven Biotherapeutics to Host Conference Call in Conjunction with Data Presentation in May
Rheos Medicines, backed by Third Rock Ventures, launched with a $60 million Series A financing. The company will focus on immunometabolism to treat disease.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical company advancing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer, today announced that it has entered into a definitive agreement with several institutional and accredited investors for the purchase of 7,968,128 shares of its common stock
Eleven Biotherapeutics’ VISTA Trial of Vicinium™ in NMIBC on-track for topline three-month data in mid-2018.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing novel product candidates based on its Targeted Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, president and chief executive officer, will present a company overview at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 12:00 p.m. ET in Boston.
Mr. Fitzgerald had been serving in the role on an interim basis since October 2017.
Eleven Biotherapeutics Announces Chief Scientific Officer to Chair a Session at the Antibody Engineering and Therapeutics Meeting
Eleven Biotherapeutics announced that Dr. Gregory Adams, Chief Scientific Officer, will chair a session focused on antibody drug conjugates and fusion proteins at the Antibody Engineering and Therapeutics Meeting in San Diego, CA.
Cash and cash equivalents were $11.3 million as of September 30, 2017, compared to $25.3 million as of December 31, 2016.
Eleven Biotherapeutics announced it will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2017 to report its third quarter 2017 financial results and provide a corporate update.
Eleven Biotherapeutics announced the pricing of an underwritten public offering of 5,525,000 shares of its common stock.
Eleven Biotherapeutics announced the appointment of Richard F. Fitzgerald as Interim CFO, effective October 20, 2017.
Eleven Bio Announces Completion Of Vicinium Manufacturing For Ongoing Clinical Trials In Non-Muscle Invasive Bladder Cancer